In a significant move aimed at modernizing the landscape of respiratory clinical research, Evinova—a clinical development technology company under the AstraZeneca umbrella—has announced a strategic partnership with Lothar Medical. This collaboration is set to integrate Evinova’s robust Unified Trial Solution with Lothar Medical’s advanced portable pulmonary function monitoring devices. By bridging the gap between sophisticated diagnostic hardware and digital clinical trial management, the partners aim to create a more connected, efficient, and data-rich environment for sponsors, clinical trial sites, and patients worldwide.
Main Facts: A Convergence of Digital Infrastructure and Diagnostic Precision
The core of this partnership lies in the technical integration of two industry-leading platforms. Evinova’s "Unified Trial Solution" is a GxP-validated digital ecosystem that has already established a global footprint, currently deployed across more than 4,000 clinical trial sites in 54 countries. Designed to support the full spectrum of trial methodologies—including traditional, hybrid, and decentralized models—the platform acts as a central nervous system for clinical data collection and patient management.
Lothar Medical, meanwhile, brings to the table its proprietary portable pulmonary function monitoring technology. Unlike traditional setups that require bulky, stationary equipment, Lothar Medical’s devices consolidate three vital measurements into a single, compact unit: Fractional Exhaled Nitric Oxide (FeNO), oscillometry, and spirometry.
By integrating these devices with Evinova’s digital interface, the partnership aims to solve a persistent industry challenge: the fragmentation of data. The integrated system will allow for the seamless transmission of primary and secondary endpoints—such as Forced Expiratory Volume (FEV1), Peak Expiratory Flow (PEF), and FeNO levels—directly into the trial database. Furthermore, it incorporates exploratory measures, including large and small airway resistance and reactance, providing researchers with a more granular view of respiratory health than previously possible in a portable format.
Chronology: The Path to Integration
The announcement follows a period of increasing pressure within the pharmaceutical industry to improve recruitment efficiency and data integrity in respiratory medicine.
- Initial Development: Over the past several years, Lothar Medical worked to achieve international regulatory milestones, securing CE-marking, MHRA Class IIa registration, and ISO 13485 certification for its ALDS (Ambulatory Lung Health System) and ALDS PRO product lines.
- Scaling Digital Infrastructure: Simultaneously, Evinova, leveraging the clinical development expertise of its parent company, AstraZeneca, expanded its Unified Trial Solution to become a global standard for trial management, focusing on reducing administrative burdens for clinical sites.
- The Strategic Alignment: Recognizing the synergy between digital trial management and real-time diagnostic hardware, the two companies engaged in discussions to harmonize their platforms. This alignment was driven by the recognition that respiratory conditions—such as asthma and chronic obstructive pulmonary disease (COPD)—require precise, longitudinal data that is often compromised by manual data entry errors or equipment inconsistencies.
- Formalization: The partnership was finalized in the third quarter of 2026, setting the stage for immediate deployment across upcoming respiratory trial protocols.
Supporting Data: Addressing the Respiratory Research Gap
Respiratory research is historically fraught with challenges related to participant screening and longitudinal data collection. The clinical community has long struggled with the "diagnostic gap," where the real-world diagnosis of a patient does not perfectly align with the specific inclusion criteria of a clinical trial.
The Recruitment Challenge
Respiratory conditions are frequently under-diagnosed or diagnosed at late stages. This leads to a smaller pool of eligible participants and higher screen-failure rates. By utilizing Lothar Medical’s three-in-one diagnostic unit during the screening phase, clinicians can perform rapid, accurate lung function assessments at the point of care. This ensures that only patients who meet precise physiological criteria are enrolled, thereby reducing costs and accelerating the timeline for patient recruitment.
Improving Data Quality
The integration is expected to significantly enhance data quality through two primary mechanisms:
- Reduced Workflow Complexity: By consolidating multiple diagnostic workflows into a single device, sites can reduce the administrative burden on staff and the physical footprint required for testing.
- Digital Coaching and Automated Validation: The interface between the device and the Evinova platform includes automated validation checks. These digital guardrails ensure that tests are performed correctly and that data is captured in real-time, minimizing the risk of human error associated with manual logging or offline device syncs.
Official Responses and Strategic Vision
The leadership teams of both organizations view this partnership not just as a product integration, but as a fundamental shift in how respiratory trials will be conducted in the future.
Tim Harrison, Chief Medical Officer at Evinova, emphasized the transformative potential of the collaboration. "The partnership between Lothar Medical and Evinova represents an exciting step forward for respiratory clinical research," Harrison stated. "By combining innovative respiratory diagnostics with cutting-edge digital trial capabilities, we have the opportunity to redefine how respiratory studies are delivered and accelerate the development of more personalized care for patients."
The sentiment is shared by those at Lothar Medical, who see the Evinova platform as the ideal vehicle for their technology to reach a broader clinical audience. By automating the data flow, the companies are moving away from the era of "disconnected diagnostics" toward a future of "integrated trial intelligence."
Implications for the Future of Respiratory Medicine
The implications of this partnership extend far beyond the immediate convenience of trial sites.
Personalized Medicine and Precision Diagnostics
The ability to track both small and large airway resistance in real-time provides researchers with deeper insights into the pathophysiology of diseases like interstitial lung disease and bronchiectasis. As medicine moves toward more personalized treatment pathways, the ability to correlate symptom diaries with precise, objective physiological data will be paramount in identifying which patient subgroups respond best to specific therapies.
The Shift Toward Hybrid and Decentralized Trials
As the industry continues to pivot toward decentralized clinical trials (DCTs), the need for reliable, portable, and connected hardware has never been greater. The Evinova-Lothar collaboration provides a scalable solution for trials that take place outside of traditional hospital settings. This is particularly relevant for chronic conditions where patient mobility might be limited, or where frequent clinic visits are a barrier to trial participation.
Operational Efficiency for Sponsors
For trial sponsors, the primary benefit is the acceleration of the "time-to-data." In the high-stakes environment of drug development, the speed at which a sponsor can analyze primary endpoints can shave months off a development program. The automated data capture provided by this partnership reduces the time required for data cleaning and query resolution, allowing for faster decision-making throughout the lifecycle of the trial.
Conclusion
The partnership between Evinova and Lothar Medical serves as a blueprint for the future of clinical development. By marrying high-fidelity diagnostic hardware with a sophisticated, globally-validated digital platform, the companies are addressing the most critical bottlenecks in respiratory research.
As they deploy this integrated solution, the industry will be watching closely to see if this model of "connected intelligence" can indeed lead to faster, more accurate, and more patient-centric clinical trials. If successful, the collaboration could set a new standard for how we measure lung health in clinical settings, ultimately paving the way for more effective treatments for the millions of people living with respiratory disease.
In an era where technology is finally catching up to the complexities of human biology, this union of digital and diagnostic expertise is a timely, strategic, and highly necessary advancement for the global clinical research community.
About the Author
